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Abstract
Background: Pulmonary vascular diseases are increasingly recognised as important clinical conditions. Pulmonary
hypertension associated with a range of aetiologies is difficult to treat and associated with progressive morbidity and
mortality. Current therapies for pulmonary hypertension include phosphodiesterase type 5 inhibitors, endothelin receptor
antagonists, or prostacyclin mimetics. However, none of these provide a cure and the clinical benefits of these drugs
individually decline over time. There is, therefore, an urgent need to identify new treatment strategies for pulmonary
hypertension.
Methodology/Principal Findings: Here we show that the PPARb/d agonist GW0742 induces vasorelaxation in systemic and
pulmonary vessels. Using tissue from genetically modified mice, we show that the dilator effects of GW0742 are
independent of the target receptor PPARb/d or cell surface prostacyclin (IP) receptors. In aortic tissue, vascular relaxant
effects of GW0742 were not associated with increases in cGMP, cAMP or hyperpolarisation, but were attributed to inhibition
of RhoA activity. In a rat model of hypoxia-induced pulmonary hypertension, daily oral dosing of animals with GW0742
(30 mg/kg) for 3 weeks significantly reduced the associated right heart hypertrophy and right ventricular systolic pressure.
GW0742 had no effect on vascular remodelling induced by hypoxia in this model.
Conclusions/Significance: These observations are the first to show a therapeutic benefit of ‘PPARb/d’ agonists in
experimental pulmonary arterial hypertension and provide pre-clinical evidence to favour clinical trials in man.
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Introduction
Pulmonary hypertension comprises a spectrum of disorders with a
multitude of aetiologies. The condition is defined clinically as a mean
pulmonary artery pressure (mPAP) of greater than 25 mmHg
(3.3 kPa) at rest [1]. Pulmonary hypertension is characterised
pathologically by pulmonary arterial vasoconstriction, vascular
remodelling and intraluminal thrombosis. These features predomi-
nantly affect small resistance pulmonary arterioles leading to a clinical
picture of insidious dyspnoea progressing in parallel with diminishing
pulmonary artery luminal diameter and increasing pulmonary
vascular resistance. In the early stages the thin walled right ventricle
is able to compensate by working harder leading to right ventricular
hypertrophy. Eventually however, the adaptive capability of the right
ventricle is exceeded with the development of right ventricular failure
and subsequently death. Untreated, idiopathic pulmonary hyperten-
sion has a highmortality with a median survival of just 2.8 years and a
5 year survival rate of only 34% [2].
Intensive research efforts have focussed on the identification of
aberrant pathophysiological signalling pathways at the level of the
pulmonary arteriole. Vasoconstriction and the drive to remodel
are limited by the release of vaso-protective hormones from the
endothelium. These hormones include nitric oxide (NO) and
prostacyclin. The endothelium also produces a powerful constric-
tor hormone, endothelin (ET)-1, which additionally stimulates
smooth muscle cells to proliferate and vessels to remodel [3].
Pulmonary hypertension is associated with deficiencies in these
pathways; an underproduction of dilator hormones and/or an
overproduction of constrictors. In line with this, the current
therapies available to treat pulmonary arterial hypertension are
based on pharmacological intervention of each of these endothe-
lium-derived hormones [4].
Prostacyclin and prostacyclin mimetics are a cornerstone of
therapy for patients with pulmonary hypertension. They have
been shown to improve exercise capacity and pulmonary
haemodynamics, as well as showing long term survival advantage
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[5,6]. An important downside of prostacyclin therapy is that it
must be administered via continuous intravenous or subcutaneous
infusion, or via multiple inhaled treatments throughout the day
and night. This is not only inconvenient for patients, but
interruption of an intravenous infusion may cause fatal rebound
pulmonary arterial hypertension.
Prostacyclin formed by activated vessels [7], acts via cell surface
IP receptors linked to activation of adenylate cyclase. Recent
evidence suggests that prostacyclin could also be a ligand for the
nuclear PPARb/d receptors which act to modulate gene
expression [8,9]. In addition, we have recently shown that the
prostacyclin mimetic treprostinil sodium, which is currently
licensed for the treatment of pulmonary hypertension, activates
PPARb/d receptors in lung fibroblasts [10] and in human platelets
[11]. There are three PPAR receptors; PPARa, PPARb/d and
PPARc. Orally active PPARa and PPARc agonists are already
used in clinical practice for the treatment of hyperlipidaemia and
type 2 diabetes. They are well tolerated and have a good safety
profile. Moreover, pre-clinical studies have shown that the PPARc
ligands rosiglitazone, pioglitazone and troglitazone have some
protective effects in the chronic hypoxia and monocrotaline
models of pulmonary arterial hypertension in rats [12,13,14] with
significant reductions in pulmonary vascular remodelling in both
these models. However, the possibility that PPARb/d agonist may
affect pulmonary hypertension has not yet been addressed.
Thus, here we investigated the effects of PPARb/d agonists
(including GW0742) on pulmonary artery tone in vessels from rats
and mice. We have compared responses in pulmonary arteries
with those seen in mesenteric arteries and the aorta. We have also
used vessels from genetically modified mice where IP or PPARb/d
genes have been deleted to address the role of each receptor in
responses induced by PPARb/d agonists. The effect of PPARb/d
agonists on cAMP, cGMP, membrane potential or Rho kinase
activity in arterial vascular tissue was studied. Finally, we
investigated the effects of the PPARb/d agonist GW0742 on
markers of pulmonary hypertension induced by hypoxia in rats.
Methods
Myography
Male C57BL/6 mice (20–30 g) were killed by lethal exposure to
carbon dioxide followed by cervical dislocation. The mice were
maintained and killed in accordance with Home Office guidelines
for the use of experimental animals. The heart and lungs were
removed as a block and placed into physiological salt solution
(PSS; composition in mM) containing NaCl 119, KCl 4.7, CaCl2
2.5, MgSO4 1.17, NaHCO3 25, KH2PO4 1.18, EDTA 0.027 and
glucose 5.5. The heart lung block was pinned out in a dissecting
dish containing PSS, to allow the descending thoracic aorta to be
carefully cleaned of fat and connective tissue. Following this, the
first order pulmonary arteries were identified and carefully
dissected from surrounding structures, connective tissue and fat.
These arteries were stored in fresh PSS at room temperature until
use. The mesenteric bed was removed, pinned out on a silicon
based Petri dish before being cleaned of fat and connective tissue.
Second order arteries were dissected and loaded on to wire
myographs as described previously [15]. For some experiments
3rd/4th order pulmonary artery from male Wistar rats (250–270 g)
were used. For other studies, responses of vessels from genetically
modified male mice in which either the IP or PPARb/d receptors
were deleted (IP2/2 or PPARb/d2/2) were compared with those
seen in vessels from wild type control animals. IP2/2 mice were a
generous gift from Professor Maria Belvisi and Dr Sarah Maher
located locally at Imperial College [16]. Colonies of PPARb/d2/2
mice were generated by Professor Be´atrice Desvergne [17].
Vascular tissue from PPARb/d 2/2 and the corresponding wild
type mice were collected from Switzerland and transported at
room temperature in sterile DMEM (0% FCS) before being used
(within 6 hours) experimentally in London. For myography
experiments n-values refer to tissues from individual animals.
Isometric Myograph Recordings
Using 2 tungsten wires (diameter 40 mm), 2 mm long segments of
artery were mounted in a four channel Mulvany-Halpern
myograph (Model 610 M, Danish Myo Technology, Aarhus,
Denmark) and supported in PSS, at a temperature of 37uC,
bubbled with 95%O2 and 5% CO2. After 30 minutes the tension of
the aortic segments and mesenteric arteries were normalised to a
tension equivalent to that generated at 90% of the diameter of the
vessel at 100 mmHg, using standard procedures as described
previously [15]. The pulmonary artery segments were normalised to
a tension of 7.5 kPa which is roughly half that of the aortic segments
given that the pulmonary circulation is exposed to lower pressures in
vivo. Changes in arterial tone were recorded via a PowerLab/800
recording unit (ADinstruments). In order to assess the viability of
vessels they were first challenged twice with high potassium solution
(KPSS; composition in mM: KCl 123.7, CaCl2 2.5, MgSO4 1.17,
NaHCO3 25, KH2PO4 1.18, EDTA 0.027 and glucose 5.5) which
induces vasoconstriction in a viable tissue.
Drug Treatments
Tissues contracted with U46619 or with phenylephrine.
Cumulative contractile concentration response curves to the
thromboxane mimetic U46619 were constructed (1 nM to 1 mM)
before the myograph baths were washed out three times with PSS and
the blood vessels allowed to equilibrate back to baseline. Vessels were
then precontracted with the EC80 concentration of U46619. Once a
stable contraction was achieved, cumulative concentration response
curves to the PPARb/d agonist GW0742 (1–100 mM), and other
specified vasodilators were constructed in pulmonary artery,
mesenteric artery and aortic vascular rings. The vehicle control for
GW0742 was DMSO with the final concentration in experiments
using mouse tissue being 0.6% v/v and in experiments using rat tissue
being 0.8% v/v, where vessels were contracted with U46619, or 0.4%
where contracted with hypoxia. In some experiments the contractile
agent phenylephrine was used in place of U46619. As with U46619,
where phenylephrine was used, cumulative contractile concentration
response curves (1 nM to 10 mM) were constructed to determine the
EC80 concentration for each tissue. In additional experiments, selective
inhibitors were added between 15–45 minutes prior to addition of the
contractile agent, and dilator experiments repeated as above.
Tissues contracted with hypoxic. In vitro hypoxia elicits a
transient constriction of pulmonary arteries within 1–2 min. This
is followed by a more sustained response which, in our setup,
decays over 40 minutes and, as such, protocols using hypoxia as a
contractile stimuli, are time limited. For this reason, just two
concentrations of GW0742 were tested as relaxants of hypoxia-
induced vasoconstriction. For these experiments 3rd/4th order rat
pulmonary artery was used and mounted in myographs. Tissues
were stretched to give an equivalent transmural pressure of 4 kPa
as previously described [18,19]. Vessels were then primed with
submaximal concentrations of pheylephrine (30 nM) and further
contracted with two successive challenges of hypoxia. The relaxant
effects of GW0742 (10–30 mM) or vehicle (DMSO; 0.4%) were
examined during the second, and more stable, exposure to
hypoxia. For comparison, the relaxant effects of GW0742 on
parallel pulmonary artery rings contracted with U46619 (100 nM)
were studied.
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Measurement of membrane potential. Smooth muscle
cells of whole mesenteric arteries were impaled with sharp glass
electrodes filled with 2 M KCl, tip resistances ,80–100 MV, and
membrane potential and tension were measured simultaneously
[20]. Second-order rat mesenteric arteries were incubated with or
without 100 mM L-NG-nitro-L-arginine methyl ester (L-NAME)
for 20 min and precontracted with the EC80 concentration of
phenylephrine. Once a stable contraction was obtained arteries
were exposed to cumulative concentrations of GW0742, as above,
and the tension and membrane potential were measured
continuously for up to 20 min. At the end of the experiment
30 mM of acetylcholine was added as a control agent to induce
membrane potential changes [20].
Measurement of adenosine 39,59 cyclic monophosphate
(cAMP), guanosine 39,59 cyclic monophosphate (cGMP) or
RhoA kinase activity in aortic rings. Aorta was removed and
cleared of connective tissue as described above. Aortic rings of
2 mm width were cut and placed into individual wells of a 96-well
culture plate containing 100 ml of Dulbecco’s modified eagle
medium containing 10% heat-inactivated fetal bovine serum,
penicillin (100 U/ml), streptomycin (100 mg/ml), and non-
essential amino acids (1% vol/vol) and allowed to equilibrate for
30 min in an atmosphere of 5% CO2 at 37uC and then, replaced
with fresh medium. For these experiments n values were defined as
separate segments of aorta, where for each experiment, tissue from
at least 4 separate animals was used.
cAMP and cGMP assay. For measurement of cyclic
nucleotides, the pan-phosphodiesterase inhibitor, 3-isobutyl-1-
methylxanthine (IBMX) was then added in a volume of 10 ml to
give a final concentration in the well of 300 mM for 15 minutes.
Drugs or DMSO (final concentration of 0.03%) were then added
in volumes of 10 ml to give the following final concentrations in the
well: 10 mM sodium nitroprusside (SNP); 10 mM forskolin; 30 mM
GW0742. Tissues were incubated for a further 20 minutes before
the reaction was stopped and tissues lysed by replacing the
medium with ice cold HCl (0.1 M). Protein content of extracted
samples was measured with Bradford’s reagent. Samples were then
diluted 1:3 with the assay buffer provided with the cAMP or
cGMP ELISA kits (see below) to provide a final concentration in
the range of 1-2 mg per well, depending upon individual
experiments. cAMP and cGMP were measured using
commercial enzyme-linked immunosorbent assay (ELISA) kits
according to manufacturer’s instructions (Cayman Chemicals,
Ann Arbor, MI; cAMP and cGMP ELISA kits 581001 and
581021 respectively).
RhoA Activation Assay
RhoA activation was measured using a commercial kit (G-
LISATM RhoA Activation Assay Biochem KitTM; from Cytoskel-
eton) which detects active GTP-bound RhoA. For these
measurements aortic rings were placed in warm DMEM and
allowed to equilibrate for 30 min, as above, followed by the
addition (in 10 ml volumes) of Rho associated protein kinase
(ROCK) inhibitor Y27632 or GW0742 at final concentrations in
the well of 30 mM or vehicle (DMSO) for 20 min, before adding
U46619 or vehicle in a volume of 10 ml to produce a final
concentration of 10 nM and incubating for a further 15 min. The
reaction was stopped by adding cold PBS (200 ml) and the aortic
rings were snap–frozen using liquid nitrogen. Samples were
homogenized using an Ultraturax homogenizer in lysis buffer
containing the provided protease inhibitors. The homogenate was
centrifuged at 10 000 g for 2 minutes at 4uC to remove cellular
debris. Protein concentration was measured using the assay
provided with the kit (Precision RedTM Advanced Protein) and
1.5 mg of tissue extract added per well. Data were expressed as fold
change versus control (vehicle-treated) samples.
Ethics Statement. All animal procedures were carried out
under specific protocols approved by the Home Office.
Chronic hypoxia model of pulmonary hypertension in
vivo. Male Sprague-Dawley rats (Harlan, Indianapolis, IN)
weighing between 230–250 g were randomised to normoxia (21%
inspired O2; n= 10) or hypoxia (10% inspired O2; n = 29) for 21
days. They were treated with vehicle alone or vehicle plus the
PPARb/d agonist GW0742 at 30 mg per kg for 23 days. This dose
of drug was recommended by the supplier, GSK and consistent
with other studies using the compound in vivo [21]. Fresh food,
water and clean cages with bedding were provided twice weekly.
Light was maintained on a 12 hour cycle and humidity was 55%
with a temperature of 19–23 degrees Celsius. The animals were
monitored daily and weight was checked. Vehicle or vehicle plus
drug was administered once daily by oral gavage.
Haemodynamic measurements and tissue procurement.
At the end of 3 weeks, rats were anaesthetised with fentanyl-
fluanisone-midazolam (2.7 ml/kg body weight intraperitoneally).
The ventral neck area was cleaned with 70% ethanol and an L
shaped incision measuring 2 cm by 2 cm was made starting in the
midline under the chin and extending to the distal aspect of the
right clavicle in order to expose the right internal jugular (RIJ)
vein. A precurved catheter was inserted into the RIJ and a
pressure tracing was transduced and recorded by PowerLab Data
Acquisition system (ADInstruments Limited, Oxfordshire, UK).
To measure right ventricular systolic pressure the catheter was
passed through the right atrium into the right ventricle. It should
be noted that that whilst right ventricular systolic pressure is used
as a surrogate for pulmonary artery pressure [22,23], it is not a
direct measure. A second catheter was inserted into the left carotid
artery. This was located by blunt dissection just lateral to the
midline position. The carotid systolic arterial pressure was
recorded using the PowerLab Data Acquisition system.
Following removal of the carotid catheter, fresh arterial blood
was collected for measurement of haematocrit. The abdominal
cavity was opened and rats were killed by exsanguination via the
abdominal inferior vena cava. Withdrawn blood was centrifuged
at 6000 rpm for 6 minutes to provide platelet free plasma. The
chest was opened and left atrium removed. A needle was inserted
into the right ventricle and 20 mls of heparinised saline (1:100)
were flushed through the lungs to clear the pulmonary vasculature
of blood. The heart lung block was then removed from the chest.
The right ventricle was carefully dissected from the septum plus
left ventricle and each part weighed individually and used to
calculate the ratio of wet right ventricle weight to wet septum plus
left ventricle weight and body weight. The left lung was removed
in its entirety and weighed. 10% formalin was injected into the
bronchial tree via the left main bronchus and the inflated left lung
was stored in formalin for later histological analysis.
Microscopy and lung morphometric analysis. Transverse
sections of fixed lung were stained with VanGiessen and alpha actin
stains to identify elastin and smooth muscle, respectively, in vessel
walls. Distal pulmonary vessels (,100 mm) were counted and the
degree of muscularisation for each vessel was assessed [24] as fully
muscularised (two distinctive and continuous elastic lamina),
partially muscularised (second elastic membrane not continuous
,75%) and non—muscularised (single elastic membrane).
Materials. GW0742 was a kind gift from Timothy Willson,
GlaxoSmithKline (USA). GW0742 was suspended in gum
tragacanth (Sigma, UK) for administration via oral gavage, and
diluted in DMSO for myography experiments. All other reagents
were from Sigma (UK), unless otherwise stated.
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Results
In Vitro Study of GW0742 in Blood Vessels
Relative responses of PPAR agonists as dilator agents in
pulmonary artery, aorta and mesenteric vessels from
rodents. In U46619 contracted mouse pulmonary artery two
chemically distinct PPARb/d agonists, GW501516 and GW0742,
induced acute vascular relaxant responses (Figure 1a). GW0742 also
induced relaxant responses in isolated pulmonary arteries from rats
(Figure 2 c/d). The PPARc agonist, rosiglitazone, also induced
relaxant responses in mouse pulmonary artery, although its activity
was less potent and efficacious than that seen with PPARb/d
agonists (Figure 1a). In contrast to GW0742, GW501516 or
rosiglitazone, the PPARa agonist bezafibrate did not induce
significant relaxant responses in mouse pulmonary artery (Figure 1a).
Relaxant responses of the PPAR agonists were also examined
using murine aorta (Figure 1b) and mesenteric artery (Figure 1c)
vascular rings. In aorta, the PPARb/d agonist, GW0742, was an
active vaso-relaxant, but was less potent and efficacious than in
pulmonary artery. Moreover, in aortic tissue GW0742 was a
similarly potent vaso-relaxant as rosiglitazone (Figure 1b). In the
aorta bezafibrate produced small, but significant, relaxation
responses. In mouse mesenteric arteries (Figure 1c) GW0742
induced potent and profound relaxant responses, similar to those
seen in the pulmonary artery (Figure 1a). However, in the
mesenteric artery neither rosiglitazone nor bezafibrate induced
significant relaxant responses (Figure 1c).
Characterisation of vascular relaxation induced by
GW0742. The dilator effects of GW0742 on mouse pulmonary
artery were found to be independent of endothelial derived nitric
oxide because pre-incubation of tissues with the nitric oxide
synthase inhibitor L-NAME (1 mM) did not prevent responses
(Figure 2a). Similarly in mesenteric artery and in aorta, removal of
endothelium did not affect the relaxation induced by GW0742
(data not shown). In line with observations made using U46619,
GW0742 induced similar relaxant responses when the pulmonary
artery was contracted with phenylephrine (figure 2b). Similarly to
results seen with mouse pulmonary artery, GW0742 relaxed 3rd/
4th order branch pulmonary artery from rats contracted with
U46619 (Figure 2c) or with hypoxic challenge (Figure 2d).
Roles of prostacyclin IP and PPARb/d receptors in the
vascular relaxation induced by GW0742. The role of known
prostacyclin receptors (cell surface IP and cytosolic PPAR b/d
receptors) in the relaxant responses induced by GW0742 was
assessed by comparing responses in tissues from wild type and gene
deleted mice. GW0742 induced relaxant responses in mouse
pulmonary artery and mesenteric arteries from wild type and
IP2/2 mice (Figure 3). The relaxation induced by GW0742 in
mesenteric artery was unaffected by IP gene deletion (Figure 3a).
The response induced by GW0742 in pulmonary artery from IP2/2
mice showed a small but significant reduction compared to
responses in tissue from paired wild type mice (Figure 3b). Aorta
was not studied from IP2/2 mice as, in this vessel, IP receptors are
not linked to vaso-relaxation. As expected, and by way of a
phenotype control, the relaxant response of treprostinil sodium
(which activates PPAR b/d receptors in some tissues and IP
receptors in all tissues) was greatly reduced in mesenteric arteries
from IP2/2 mice (data not shown). The relaxant effect of GW0742
on pulmonary artery (Figure 4a) and mesenteric artery (4b) was
unaffected by deletion of the PPAR b/d gene. However, by
contrast, the relaxant effects of GW0742 in aorta was significantly
blunted in tissue from PPAR b/d2/2 mice compared to those in
matched wild type control animals (Figure 4c).
Role of known smooth muscle relaxant pathways in the
responses induced by GW0742 in blood vessels. Relaxation
of blood vessels is generally mediated by at least one of four classic
pathways. These include increases in cGMP or cAMP, activation/
inhibition of ion channels resulting in hyperpolarisation of smooth
muscle, or inhibition of RhoA. Vascular rings were prepared and
incubated with GW0742 or activators/inhibitors of guanylate
cyclase, adenylate cyclase or ROCK before reactions were stopped
and samples extracted from the tissue. GW0742 did not cause any
increases in cGMP (Figure 5a) or cAMP (Figure 5b). As expected,
the nitrovasodilator sodium nitroprusside (SNP) increased cGMP
(Figure 5a) levels whilst, forskolin, which activates adenylate cyclase,
Figure 1. Effects of PPAR agonists on vascular tissue. The vaso-
relaxant responses of three different PPAR agonists in (A) pulmonary artery,
(B) aorta and (C) mesenteric artery. GW501516 or GW0742, which activate
PPARb/d, rosiglitazone, which activates PPARc or bezafibrate, which
activates PPARa, were added to U46619 [EC80] contracted arteries in
increasing concentrations. Responses of vehicle (DMSO; final accumulated
maximum of 0.6%) are shown as ‘vehicle control’. The data is the mean6
standard error of the mean for n=428 experiments. Drug induced
responses were compared with time control using two-way ANOVA and a
p value of ,0.05 was assumed statistically significant and denoted by*.
Where p.0.05, the lack of statistical significance is denoted by ns.
doi:10.1371/journal.pone.0009526.g001
PPAR in Pulmonary Hypertension
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9526
increased cAMP (Figure 5b). By contrast to observations with
cGMP and cAMP we found evidence to suggest that GW0742
inhibits RhoA activity in vascular tissue. GTP-bound RhoA was
increased in vascular tissue when stimulated with the known
activator of this system, U46619. GTP-bound RhoA was inhibited
by the classical inhibitor Y27632 and by GW0742 (Figure 6). In
separate experiments we investigated the ability of GW0742 to
induce hyperpolarization in segments of mesenteric artery by
measuring membrane potential in the smooth muscle component of
the tissue. GW0742 had no effect on membrane potential at
concentrations up to 10 mM (Figure 7; which dilate this tissue by
approximately 75%). However, at concentrations of 30 mM
significant hyperpolarisation was noted (Figure 7). Maximum
hyperpolarisation induced by acetylcholine (30 mM) is shown for
comparison (Figure 7).
In Vivo Study of GW0742 in a Rat Model of Hypoxia-
Induced Pulmonary Hypertension
Data from in vitro studies described above suggested that
GW0742 may be therapeutically active in pulmonary hyperten-
sion. We therefore investigated the effects of GW0742 on
physiological parameters in a rat model of hypoxia-induced
pulmonary hypertension. Rats were exposed to hypoxia or air for
3 weeks and administered GW0742 (30 mg/kg oral administration
daily) or vehicle. Drug treatments had no effect on body weight or
haematocrit (Table 1). Hypoxia induced the cardinal signs of
pulmonary hypertension including increased right heart mass
(Figure 8a), increased right ventricular systolic pressure (Figure 8b)
and remodelled pulmonary arteries (Figure 9). This study revealed
significant reductions in both right ventricular hypertrophy
(Figure 8a) and right ventricular systolic pressures (Figure 8b) in
hypoxic animals treated with GW0742 compared to hypoxic
controls. There were no significant differences in systolic arterial
pressure between the groups (Figure 8c), although the trend
appears to show higher systolic pressures in the GW0742-treated
animals compared to controls. Finally, there were no significant
differences seen in the vascular remodelling of distal pulmonary
arterioles between the hypoxic control animals and hypoxic
animals treated with GW0742 (Figure 9).
Discussion
In the current study we have demonstrated that PPARb/d
agonists induce relaxation of blood vessels, including pulmonary
artery, and protect against right heart hypertrophy associated with
hypoxia-induced pulmonary hypertension. These data suggest that
PPARb/d agonists may have therapeutic utility in the treatment of
pulmonary hypertension.
Figure 2. Characterisation of relaxant effects of GW0742 in pulmonary vessels. L-NAME (1 mM) had no effect on relaxant responses
induced by GW0742 in U46619 contracted mouse pulmonary artery (A). GW0742 induced similar relaxant responses in mouse pulmonary artery
contracted with EC80 concentrations of U46619 or phenylephrine (PE) (B). GW0742 induced relaxant responses in rat 3
rd/4th order pulmonary artery
contracted with 100 nM U46619 (C) or with hypoxia (D), vehicle control for these experiments was again DMSO at accumulated maximum
concentrations of 0.8 and 0.4% v/v respectively. Data is the mean6 standard error of the mean for n = 428. Drug induced responses were compared
with time control using two-way ANOVA and a p value of ,0.05 was assumed statistically significant and denoted by*. Where p.0.05, the lack of
statistical significance is denoted by ns.
doi:10.1371/journal.pone.0009526.g002
PPAR in Pulmonary Hypertension
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9526
GW0742 relaxed three different murine blood vessels; the aorta,
pulmonary artery and mesenteric artery. We also confirm our
observations in mouse pulmonary artery by showing that GW0742
induces vascular relaxation in rat pulmonary artery. Interestingly,
GW0742 was a more potent relaxant of pulmonary and mesenteric
artery than it was of aorta. GW0742 relaxed pulmonary artery
contracted with a range of stimuli including the thromboxane
mimetic U46619, the adrenergic agonist phenylephrine and
hypoxia applied in vitro. PPAR agonists as a class of drugs are
currently being tested for their anti-inflammatory and therapeutic
beneficial effects in a range of experimental models and clinical
trials. Our data suggest that PPARb/d agonists may also be useful
for the treatment of pulmonary hypertension. Similar suggestions
have been made for the PPARc agonist rosiglitazone [12].
However, we found that the two PPARb/d agonists we tested,
GW0742 and GW501516, were more potent than the PPARc
Figure 3. Role of IP receptors in the responses of PPARb/d
agonists in blood vessels. Relaxations induced by the PPAR b/d
agonist GW0742 in (A) mesenteric artery and (B) pulmonary artery from
wild type mice were compared to responses in tissues from IP2/2 mice.
Vessels were pre-contracted with EC80 concentrations of U46618. The
data is the mean6 standard error of the mean for n = 425 experiments.
Drug induced responses were compared using two-way ANOVA and a p
value of ,0.05 was assumed statistically significant and denoted by*.
Where p.0.05, the lack of statistical significance is denoted by ns.
doi:10.1371/journal.pone.0009526.g003
Figure 4. Role of PPAR b/d receptors in the effects of GW0742 in
blood vessels. Relaxations induced by the PPAR b/d agonist GW0742
in (A) pulmonary artery, (B) mesenteric artery and (C) aorta from wild
type mice were compared to tissue from PPAR b/d2/2 mice. Vessels
were pre-contracted with EC80 concentrations of U46619. The data is
the mean 6 standard error of the mean for n = 4 experiments. Drug
induced responses were compared using two-way ANOVA and a p
value of ,0.05 was assumed statistically significant and denoted by*.
Where p.0.05, the lack of statistical significance is denoted by ns.
doi:10.1371/journal.pone.0009526.g004
PPAR in Pulmonary Hypertension
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agonist rosiglitazone as relaxing agents of pulmonary artery,
although similar in potency as relaxants of aortic tissue. Bezafibrate
was inactive as a relaxant of pulmonary artery and the weakest of
the drugs as a relaxant of the aorta. This pharmacological analysis,
whilst limited as it is based on in vitro protocols, suggests that
PPARb/d agonists may be superior to PPARc agonists in the
treatment of pulmonary hypertension.
PPARs are classically thought of as regulators of gene induction
via genomic and non genomic mechanisms. In the case of
PPARb/d [25], as with other PPARs, the genomic pathway is
thought to involve binding to retinoid X receptor (RXR) and the
formation of heterodimers which then bind to response elements
of target genes. PPARb/d also mediates gene induction via non
genomic pathways linked to trans-repression of the anti-inflam-
matory protein BCL-6 [26]. Clearly the mechanism by which
PPAR agonists dilate vessels acutely must be mediated indepen-
dently of gene induction as the response is seen within minutes of
adding the drug. Our group has shown that agonists of PPARb/d,
including GW0742, inhibit platelet activation following just 5–10
Figure 5. Effect of GW0742 on cGMP and cAMP levels in aortic
rings. Effects of 30 mM GW0742 (GW), 10 mM sodium nitroprusside (SNP;
an activator of soluble guanylate cyclase) and 10 mM forskolin (FORSKO;
an activator of adenylate cyclase) on (A) cGMP and (B) cAMP levels in
mouse aortic rings. The data is themean6 standard error of themean for
n experiments. cGMP: vehicle control (DMSO; 0.03%) and GW0742, n = 14;
SNP, n = 9; forskolin, n = 4. cAMP: DMSO and GW0742, n = 11; SNP, n = 6;
forskolin, n = 7. Drug induced responses were compared using one-way
ANOVA followed by Dunnett’s Multiple Comparison Test. Statistical
significance was assumed where p,0.05 and is denoted by *.
doi:10.1371/journal.pone.0009526.g005
Figure 6. Effects of GW0742 on activation of Rho A in aortic
rings. Mouse aortic rings were treated with or without U46619 (10 nM)
before the additions of GW0742 and Y27632 (10 mM) or vehicle control
(DMSO; 0.03%) and the content of GTP bound RhoA was measured in
tissue extracts by ELISA. Data is the mean 6 standard error of the mean
for n= 4 experiments. Data was analysed using one sample T-test for
normalized data or by one-way ANOVA followed by Bonferroni’s
Multiple Comparison Test. Significance was defined by **p,0.01 versus
control and ##, ### p,0.01 and p,0.001 treatments with U46610
compared to respective control.
doi:10.1371/journal.pone.0009526.g006
Figure 7. Effects of GW0742 on membrane potential in
mesenteric arteries. Membrane potential in mesenteric arteries was
measured under control conditions (resting membrane potential; r.m.p.)
before GW0742 was added in a cumulative manner. Data is the mean6
standard error of the mean for n= 4. Data was analysed using one-way
ANOVA followed by Dunnett’s Multiple Comparison Test. Significance
was assumed and defined by *p,0.05 and ***p,0.001 respectively.
doi:10.1371/journal.pone.0009526.g007
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minutes of treatment [11]. Clearly with such acute exposure, and
as platelets have no nucleus, effects of PPARb/d agonists on
platelet function must also be mediated independently of gene
induction and the nucleus. Others have shown that agonists of
PPARc, such as rosiglitazone, have similar effects in platelets [27].
In platelets, our group has recently demonstrated that the non
genomic inhibitory effects of PPAR agonists are associated with
trans-repression of PKCa. [28,29]. However, inhibition of PKCa
does not seem to explain fully the relaxant effects of PPARb/d
agonists in blood vessels as, in our hands, the mixed PKC inhibitor
Go¨6983 did not mimic the effects of GW0742 in pulmonary
artery. However, Go¨6976, which also inhibits PKC, did induce
limited relaxant responses (unpublished observations). How then
do PPARb/d agonists relax blood vessels?
In blood vessels smooth muscle relaxation can be brought about
by one or more well defined pathways [8]. These include the (i)
nitric oxide-cGMP, (ii) adenylate cyclase-cAMP, (iii) RhoA kinase
and (iv) activation of potassium channels leading to hyperpolar-
isation. In this study we show that the dilator effect of GW0742 in
pulmonary artery was mediated independently of endothelial
nitric oxide, as responses were not prevented by the nitric oxide
synthase inhibitor L-NAME. We next explored the biochemical
pathways that GW0742 might modulate in blood vessels in order
to better understand the mechanism by which vessel relaxation
occurs in response to this drug. Biochemical approaches are
generally limited by tissue source and in these experiments we
found that pulmonary artery was too small to obtain reliable
samples after treatment and extraction. We therefore used aorta
for biochemical studies because it is larger, providing more tissue
for extraction, and can be cut into sections allowing for the
inclusion of internal controls. We found that GW0742 did not
increase cGMP or cAMP but did inhibit activation of the RhoA
kinase pathway induced by U46619. Further, in order to
investigate the effects of GW0742 on potassium channels we
measured membrane potential in the smooth muscle component
of mesenteric arteries incubated with GW0742. Mesenteric
arteries were used for this protocol as the technique is well
validated for this tissue. Results from these experiments were less
clear. At concentrations where vasodilatation was approximately
75% of induced tone, no hyperpolarisation was detected.
However, at maximal concentrations of drug we did note a
significant hyperpolarisation response. Whilst it seems that these
observations cannot explain completely the effects of GW0742 in
the vasculature, they suggest a mechanism independent of cGMP
and cAMP and implicate an action on RhoA kinase and a partial
action on potassium channels. It should be noted however, that
vessels of different anatomical locations can utilise different
Table 1. Biometric data.
Body weight at
start of experiment
(g+/2SD)
Body weight after
21 days hypoxia
(g+/2SD)
Haematocrit
(%+/2SD)
Normoxic control
(n=4)
237+/26 295+/222 42+/23
Normoxic treated
(n=6)
236+/210 292+/217 44+/23
Hypoxic control
(n=17)
263+/216 285+/222 64+/28
Hypoxic treated
(n=12)
260+/219 284+/223 65+/24
doi:10.1371/journal.pone.0009526.t001
Figure 8. Effect of treatment with GW0742 on parameters of
pulmonary hypertension in the chronic hypoxia rat model.
Effect of normoxia versus hypoxia and treatment with GW0742 (30 mg/
Kg) versus vehicle control male Sprague-Dawley rats on (A) the ratio of
right ventricular to left ventricular plus septal weight and body weight,
(B) the right ventricular systolic pressure (RVSP) and (C) the carotid
systolic arterial pressure (SAP). The data is mean6 standard error of the
mean for n = 426 for normoxic animals and 12–17 for hypoxic animals.
Data were compared using one-way analysis of variance followed by a
Bonferroni’s multiple comparison test. Statistical significance was
assumed where p,0.05 and is denoted by * and ns (not significant)
where p,0.05.
doi:10.1371/journal.pone.0009526.g008
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Figure 9. Effect of normoxia versus hypoxia and treatment with GW0742 (30 mg/kg) versus vehicle control on lung morphology
and arteriole mascularisation in male Sprague-Dawley rats. Sections were stained with Van Giessen stain and pictures shown are
representative samples. Histological features of remodelling secondary to hypoxia are the presence of a clear double elastic lamina and increased
smooth muscle staining (indicated by arrows). Lungs were from animals in (A) normoxic, (B) normoxic treated with GW0742, (C) hypoxic or (D)
hypoxic treated with GW0742 conditions. (E) Total number of fully muscularised compared with partially muscularised pulmonary arterioles in a
single lung slice, mean 6 standard error of the mean for n = 426 for normoxic animals and 12–17 for hypoxic animals.
doi:10.1371/journal.pone.0009526.g009
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signalling pathways. The mechanism by which GW0742 induces
vascular relaxation in the pulmonary circulation remains the
subject of investigation.
GW0742 is a potent activator of PPARb/d receptors with EC50
concentrations in the low nM range [30]. Vascular relaxation
induced by GW0742 of vessels was seen in the mM range. It is
therefore possible that ‘PPARb/d agonists’ are inducing effects on
blood vessels independent of the target receptor. In order to
address this we compared responses of GW0742 in blood vessels
from wild type and PPARb/d2/2 mice. Interestingly the relaxant
effects of GW0742 on pulmonary or mesenteric artery appeared to
be independent of the target receptor PPARb/d. When responses
were analysed in aorta however, there was a significant blunting in
the relaxant responses induced by GW0742. In a recent study
from our group on platelet responses of GW0742, we also found
that some, but not all inhibitory effects of GW0742 were mediated
by PPAR b/d [31]. These observations are surprising, but
interesting and show that off-target effects of drugs designed to
activate PPARb/d may have additional beneficial effects.
Prostacyclin is an endogenous hormone ligand for PPARb/d
receptors. However, prostacyclin also activates the cell surface G-
protein coupled IP receptor. We reasoned that molecules could
display promiscuity between these two types of receptors and so
investigated the role of IP in dilator effects of GW0742. GW0742
induced comparable vascular relaxant effects in mesenteric arteries
from IP2/2 mice as seen in tissue from wild type animals.
However, there was a small, but statistically significant blunting of
the ability of GW0742 to dilate pulmonary artery from IP2/2
mice compared to tissue from wild type animals. This data
suggests that whilst IP receptors may play a small role in the effects
of GW0742 in some vessels, the major functional effect of this drug
is, on the whole, independent of IP receptors.
All of the above evidence suggests that GW0742 is a good drug
candidate for the treatment of pulmonary hypertension. We
therefore investigated this possibility directly by studying the effects
of GW0742 on pathophysiological symptoms of hypoxia-induced
pulmonary hypertension in the rat. Rats placed in hypoxic
chambers for three weeks developed cardinal signs of pulmonary
hypertension including increased right ventricular systolic pres-
sure, increased right heart mass and dramatic remodelling. In this
study, as in others [22,23], right ventricular systolic pressure was
used as a surrogate for mean pulmonary artery pressure. However,
it is acknowledged that this parameter can be influenced by
cardiac effects, independent of pulmonary vascular responses.
Animals were treated with GW0742 or vehicle by daily oral dosing
for the entire duration of the model. GW0742 had no significant
effects on physiological parameters measured in rats kept under
normoxic conditions. Despite the findings that GW0742 relaxes a
range of blood vessels, it was interesting that rats treated with
GW0742 had no significant reduction in systemic arterial pressure.
This is also true for other pulmonary hypertension drugs which
relax blood vessels such as sildenafil and prostacyclin (or mimetics
such as trepostinil sodium etc). In the case of sildenafil and
prostacyclin systemic effects can be seen in patients if doses are
elevated, but a therapeutic window clearly exists for these drugs
outside systemic pressure effects [32]. In the case of GW0742 and
our study, it may be relevant that the relaxant effects of the drug
were more potent on pulmonary and mesenteric vessels than on
the aorta – it is possible that over all GW0742 dilates selected beds
(including the pulmonary circulation). However, it is equally
possible that the effective concentration of GW0742 in vivo, like
those achievable with sildenafil and trepostinil sodium, fall below
that required to affect systolic pressures.
Hypoxic animals treated with GW0742 displayed significant
reductions in right ventricular systolic pressure and in right heart
mass but, Interestingly, GW0742 had no effect on the remodelling
seen in arterioles of hypoxic animals. Changes in right ventricular
systolic pressure and right heart mass, without changes in arteriole
remodelling, suggest GW0742 is affecting pulmonary vascular
tone directly and are very much in line with what we have seen of
this drug on tissue vessels in vitro. However, as discussed above,
high concentrations of GW0742 are required to induce vessel
relaxation. It should therefore also be considered that the effects of
GW0742 in the in vivo model may result from an action directly on
the right ventricle. This possibility remains the subject of
investigation.
In the clinic, patients with pulmonary hypertension are
currently treated with oral phosphodiesterase type V inhibitors
(such as sildenafil) and/or ET receptor antagonists (such as
bosentan). As outlined above, GW0742 induces vasodilatation
independently of either of these pathways. Moreover, in animal
models like the one used here in our study sildenafil [24] or
bosentan [33] reduce arteriole remodelling. Thus, considering the
clinical profile and signalling mechanism involved, we suggest that
GW0742 will be an effective co-treatment with either phospho-
diesterase type V or ET-1 receptor antagonists for patients with
pulmonary hypertension.
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